Role of Oral Activated Charcoal in Decreasing Blood Urea, Creatinine and Phosphorous in Chronic Kidney Disease
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Assiut University
- Enrollment
- 90
- Primary Endpoint
- Mean of blood urea, creatinine and phosphorous in patients with CKD before and after oral activated charcoal
Study Overview
Brief Summary
The study aims to explore the ability of Oral activated charcoal to adsorb uremic toxins limiting the progression of chronic kidney disease and delaying the need for hemodialysis in patients with CKD stages III and IV.
To compare its effect with the effect of dry seeds as absorbents of uremic toxins
Detailed Description
In recent years, chronic kidney disease(CKD) has become a worldwide public health issue.
The main factors affecting the prognosis of patients with chronic kidney disease are its complications, including cardiovascular and cerebrovascular diseases, malnutrition, inflammation, atherosclerosis syndrome, and anemia.
The accumulation of uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, is implicated in the progression of renal failure and cardiovascular disease.
For many patients, chronic kidney disease (CKD) is a progressive condition marked by deteriorating renal function ultimately leading to end-stage renal disease (ESRD) and many patients refuse to start chronic hemodialysis.
Therapeutic approaches that decrease the level of uremic toxins are a rational method for inhibiting this progression.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with CKD stages iii and iv
- •Patients with age more than 18 years old
Exclusion Criteria
- •Patients on regular hemodialysis
- •Patients with age less than 18 years old
Arms & Interventions
1st group
Oral activated charcoal in a dose of 30 gm/day
Intervention: Activated charcoal (Drug)
2nd group
Dry seeds in a dose of 1 gm/ day
Intervention: Dry seeds (Dietary Supplement)
Outcomes
Primary Outcomes
Mean of blood urea, creatinine and phosphorous in patients with CKD before and after oral activated charcoal
Time Frame: baseline
to asses the mean of blood urea, creatinine and phosphorous in CKD patient before and after administration of activated charcoal
Secondary Outcomes
- comparison of dry seeds and activated charcoal in limitting progression of chronic kidney disease(baseline)
Investigators
Farrag Sayed Mohamed
Resident Doctor, internal medicine department, principal investigator
Assiut University